SG11202012447YA - Rapamycin analogs and uses thereof - Google Patents
Rapamycin analogs and uses thereofInfo
- Publication number
- SG11202012447YA SG11202012447YA SG11202012447YA SG11202012447YA SG11202012447YA SG 11202012447Y A SG11202012447Y A SG 11202012447YA SG 11202012447Y A SG11202012447Y A SG 11202012447YA SG 11202012447Y A SG11202012447Y A SG 11202012447YA SG 11202012447Y A SG11202012447Y A SG 11202012447YA
- Authority
- SG
- Singapore
- Prior art keywords
- rapamycin analogs
- rapamycin
- analogs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862685666P | 2018-06-15 | 2018-06-15 | |
PCT/US2019/037507 WO2019241789A1 (en) | 2018-06-15 | 2019-06-17 | Rapamycin analogs and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202012447YA true SG11202012447YA (en) | 2021-01-28 |
Family
ID=68842366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202012447YA SG11202012447YA (en) | 2018-06-15 | 2019-06-17 | Rapamycin analogs and uses thereof |
Country Status (14)
Country | Link |
---|---|
US (3) | US10980784B2 (en) |
EP (2) | EP4302827A3 (en) |
JP (2) | JP7382353B2 (en) |
KR (1) | KR20210021534A (en) |
CN (2) | CN112423843B (en) |
AU (1) | AU2019286524A1 (en) |
BR (1) | BR112020025283A2 (en) |
CA (1) | CA3103282A1 (en) |
CO (1) | CO2020015747A2 (en) |
EA (1) | EA202092692A1 (en) |
IL (1) | IL279329A (en) |
MX (1) | MX2020013630A (en) |
SG (1) | SG11202012447YA (en) |
WO (1) | WO2019241789A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019241789A1 (en) | 2018-06-15 | 2019-12-19 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
WO2020154447A1 (en) | 2019-01-22 | 2020-07-30 | Aeovian Pharmaceuticals, Inc. | Mtorc modulators and uses thereof |
TW202134234A (en) * | 2019-12-05 | 2021-09-16 | 美商奈維特製藥公司 | Rapamycin analogs and uses thereof |
JP2023530778A (en) | 2020-03-27 | 2023-07-19 | エオビアン ファーマシューティカルズ, インコーポレイテッド | MTORC1 modulators and uses thereof |
CN116322677A (en) * | 2020-07-21 | 2023-06-23 | 艾奥维安制药公司 | MTORC1 modulators and uses thereof |
EP4281463A1 (en) * | 2021-01-22 | 2023-11-29 | JANSSEN Pharmaceutica NV | Rapamycin analogs and uses thereof |
CN115097046B (en) * | 2022-07-07 | 2023-09-26 | 国药集团川抗制药有限公司 | Method for separating rapamycin and impurities thereof |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR901228A (en) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Ring gap magnet system |
ZA935112B (en) * | 1992-07-17 | 1994-02-08 | Smithkline Beecham Corp | Rapamycin derivatives |
US5260300A (en) | 1992-11-19 | 1993-11-09 | American Home Products Corporation | Rapamycin carbonate esters as immuno-suppressant agents |
WO1994025072A1 (en) | 1993-04-23 | 1994-11-10 | American Home Products Corporation | Rapamycin conjugates and antibodies |
CA2175215C (en) | 1993-11-19 | 2008-06-03 | Yat Sun Or | Semisynthetic analogs of rapamycin (macrolides) being immunomodulators |
CN1046944C (en) * | 1993-12-17 | 1999-12-01 | 山道士有限公司 | Rapamycin derivatives useful as immunosuppressants |
US5362735A (en) * | 1994-02-23 | 1994-11-08 | Smithkline Beecham Corporation | Rapamycin derivatives |
US5639600A (en) | 1994-08-05 | 1997-06-17 | The Regents Of The University Of California | Diagnosis and treatment of cell proliferative disease having clonal macrophage involvement |
JP3934705B2 (en) | 1995-05-26 | 2007-06-20 | ノバルティス ファーマ株式会社 | Cyclodextrin composition |
CA2219080A1 (en) | 1995-06-07 | 1996-12-27 | Ariad Gene Therapeutics, Inc. | Rapamycin-based regulation of biological events |
RU2158267C2 (en) | 1995-06-09 | 2000-10-27 | Новартис Аг | Derivatives of rapamycin and pharmaceutical composition based on thereof |
CA2257803C (en) | 1996-07-12 | 2008-12-02 | Ariad Pharmaceuticals, Inc. | Non immunosuppressive antifungal rapalogs |
US5922730A (en) | 1996-09-09 | 1999-07-13 | American Home Products Corporation | Alkylated rapamycin derivatives |
WO1998009970A2 (en) | 1996-09-09 | 1998-03-12 | American Home Products Corporation | Alkylated rapamycin derivatives |
US6342507B1 (en) | 1997-09-05 | 2002-01-29 | Isotechnika, Inc. | Deuterated rapamycin compounds, method and uses thereof |
US7087648B1 (en) | 1997-10-27 | 2006-08-08 | The Regents Of The University Of California | Methods for modulating macrophage proliferation using polyamine analogs |
WO2001014387A1 (en) | 1999-08-24 | 2001-03-01 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
TWI256395B (en) | 1999-09-29 | 2006-06-11 | Wyeth Corp | Regioselective synthesis of rapamycin derivatives |
JP4078074B2 (en) | 1999-12-10 | 2008-04-23 | ファイザー・プロダクツ・インク | Pyrrolo [2,3-d] pyrimidine compound |
PE20020354A1 (en) | 2000-09-01 | 2002-06-12 | Novartis Ag | HYDROXAMATE COMPOUNDS AS HISTONE-DESACETILASE (HDA) INHIBITORS |
DE60217322T2 (en) | 2001-04-27 | 2007-10-04 | Zenyaku Kogyo K.K. | Heterocyclic compound and antitumor agent containing it as an active ingredient |
TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
WO2004019973A1 (en) | 2002-08-14 | 2004-03-11 | Atugen Ag | Use of protein kinase n beta |
SG160211A1 (en) | 2003-04-03 | 2010-04-29 | Semafore Pharmaceuticals Inc | Pi-3 kinase inhibitor prodrugs |
CA2527583C (en) | 2003-05-30 | 2013-12-17 | Giorgio Attardo | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases |
AU2004257167B2 (en) | 2003-07-03 | 2012-03-29 | The Trustees Of The University Of Pennsylvania | Inhibition of Syk kinase expression |
PT1646634E (en) | 2003-07-08 | 2009-02-16 | Novartis Ag | Use of rapamycin and rapamycin derivatives for the treatment of bone loss |
US7220755B2 (en) | 2003-11-12 | 2007-05-22 | Biosensors International Group, Ltd. | 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same |
CN101031569B (en) | 2004-05-13 | 2011-06-22 | 艾科斯有限公司 | Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta |
US20060189551A1 (en) * | 2004-10-04 | 2006-08-24 | Duke University | Combination therapies for fungal pathogens |
EP2161275A1 (en) | 2005-01-19 | 2010-03-10 | Rigel Pharmaceuticals, Inc. | Prodrugs of 2,4-pyrimidinediamine compounds and their uses |
GB0504994D0 (en) | 2005-03-11 | 2005-04-20 | Biotica Tech Ltd | Novel compounds |
US20060257337A1 (en) | 2005-04-28 | 2006-11-16 | David Sherris | Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis |
KR101509440B1 (en) | 2005-05-12 | 2015-04-07 | 애브비 바하마스 리미티드 | Apoptosis promoters |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
US7402325B2 (en) | 2005-07-28 | 2008-07-22 | Phoenix Biotechnology, Inc. | Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander |
KR101538412B1 (en) | 2005-10-07 | 2015-07-22 | 엑셀리시스, 인코포레이티드 | Pyridopyrimidinone inhibitors of pi3k |
CN103819416A (en) | 2005-10-07 | 2014-05-28 | 埃克塞里艾克西斯公司 | N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
WO2007053452A1 (en) | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
SI1951724T1 (en) | 2005-11-17 | 2011-09-30 | Osi Pharmaceuticals Llc | FUSED BICYCLIC mTOR INHIBITORS |
HUE030235T2 (en) | 2005-12-13 | 2017-04-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | PI-3 Kinase inhibitors and methods of their use |
US20070203168A1 (en) | 2006-02-28 | 2007-08-30 | Zhao Jonathon Z | Isomers of rapamycin and 42-Epi-rapamycin, methods of making and using the same |
PE20080038A1 (en) | 2006-04-11 | 2008-02-22 | Smithkline Beecham Corp | THIAZOLIDINADIONE DERIVATIVES AS PI3 KINASE INHIBITORS |
CN101472930B (en) | 2006-04-26 | 2011-12-14 | 霍夫曼-拉罗奇有限公司 | Thieno [3, 2-d] pyrimidine derivative useful as pi3K inhibitor |
WO2008014449A2 (en) | 2006-07-28 | 2008-01-31 | Caracal, Inc. | Seed holder for crystal growth reactors |
SI2074122T1 (en) | 2006-09-15 | 2011-10-28 | Pfizer Prod Inc | Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors |
EP2526933B1 (en) | 2006-09-22 | 2015-02-25 | Pharmacyclics, Inc. | Inhibitors of Bruton's tyrosine kinase |
PE20081679A1 (en) | 2006-12-07 | 2008-12-18 | Hoffmann La Roche | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE |
WO2008110491A2 (en) | 2007-03-09 | 2008-09-18 | University Of Basel | Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat |
ES2557930T3 (en) | 2007-03-12 | 2016-01-29 | Ym Biosciences Australia Pty Ltd | Phenylaminopyrimidine compounds and uses thereof |
WO2008118802A1 (en) | 2007-03-23 | 2008-10-02 | Regents Of The University Of Minnesota | Therapeutic compounds |
PE20090717A1 (en) | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS |
ES2602577T3 (en) | 2008-03-11 | 2017-02-21 | Incyte Holdings Corporation | Azetidine and cyclobutane derivatives as JAK inhibitors |
US20090253733A1 (en) | 2008-04-02 | 2009-10-08 | Biointeractions, Ltd. | Rapamycin carbonate esters |
GEP20125589B (en) | 2008-05-23 | 2012-07-25 | Wyeth Llc | TRIAZINE COMPOUNDS AS P13 KINASE AND mTOR INHIBITORS |
PE20110147A1 (en) | 2008-06-20 | 2011-03-26 | Astrazeneca Ab | COMPOSITION AND PROCESS - 356 |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
ES2345241B1 (en) | 2009-03-16 | 2011-09-08 | Lipopharma Therapeutics | USE OF 2-HYDROXIDERIVATES OF POLYINSATURATED FATTY ACIDS AS MEDICINES. |
US8461158B2 (en) | 2009-03-27 | 2013-06-11 | Pathway Therapeutics Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
EP2414362B1 (en) | 2009-04-03 | 2014-06-11 | Verastem, Inc. | Pyrimidine substituted purine compounds as kinase (s) inhibitors |
US20100305093A1 (en) | 2009-04-09 | 2010-12-02 | Exelixis, Inc. | Inhibitors of mTOR and Methods of Making and Using |
EP2558092B1 (en) | 2010-04-13 | 2018-06-27 | Novartis AG | Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase 6 (cdk4/6) inhibitor and an mtor inhibitor for treating cancer |
KR20130043198A (en) | 2010-07-16 | 2013-04-29 | 피라말 엔터프라이지즈 리미티드 | Substituted imidazoquinoline derivatives as kinase inhibitors |
JO3003B1 (en) | 2011-01-14 | 2016-09-05 | Lilly Co Eli | Imidazo [4,5-c] quinolin-2-one compound and its use as pi3 kinase i mtor dual inhibitor |
EP2589383A1 (en) | 2011-11-06 | 2013-05-08 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin | FKBP subtype-specific rapamycin analogue for use in treatment of diseases |
US8808256B2 (en) | 2012-01-16 | 2014-08-19 | Johnson & Johnson Vision Care, Inc. | Eye drug delivery system |
US9072678B2 (en) | 2013-03-14 | 2015-07-07 | Pathak Holdings Llc | Methods for local drug delivery by microinjection |
US9663508B2 (en) | 2013-10-01 | 2017-05-30 | Amgen Inc. | Biaryl acyl-sulfonamide compounds as sodium channel inhibitors |
SG11201606080SA (en) | 2014-02-03 | 2016-08-30 | Vitae Pharmaceuticals Inc | Dihydropyrrolopyridine inhibitors of ror-gamma |
EP3193902A4 (en) | 2014-09-11 | 2018-03-28 | The Regents of The University of California | mTORC1 INHIBITORS |
US20160279108A1 (en) | 2015-02-24 | 2016-09-29 | University Of Kansas | Targeted mtor inhibitors |
WO2017044720A1 (en) * | 2015-09-11 | 2017-03-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
JP7348071B2 (en) | 2017-05-02 | 2023-09-20 | レヴォリューション・メディスンズ,インコーポレイテッド | Rapamycin analogs as mTOR inhibitors |
AR112834A1 (en) | 2017-09-26 | 2019-12-18 | Novartis Ag | RAPAMYCIN DERIVATIVES |
WO2019241789A1 (en) | 2018-06-15 | 2019-12-19 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
WO2020076738A2 (en) | 2018-10-12 | 2020-04-16 | Bellicum Pharmaceuticals, Inc | Protein-binding compounds |
CA3122922A1 (en) | 2018-12-18 | 2020-06-25 | Novartis Ag | Rapamycin derivatives |
WO2020154447A1 (en) | 2019-01-22 | 2020-07-30 | Aeovian Pharmaceuticals, Inc. | Mtorc modulators and uses thereof |
US20220202787A1 (en) | 2019-03-26 | 2022-06-30 | Novartis Ag | Isothiazolidine 1,1-dioxide and 1,4-butan sultone containing rapamycin derivatives and uses thereof |
JP2023530778A (en) | 2020-03-27 | 2023-07-19 | エオビアン ファーマシューティカルズ, インコーポレイテッド | MTORC1 modulators and uses thereof |
CN116322677A (en) | 2020-07-21 | 2023-06-23 | 艾奥维安制药公司 | MTORC1 modulators and uses thereof |
-
2019
- 2019-06-17 WO PCT/US2019/037507 patent/WO2019241789A1/en active Application Filing
- 2019-06-17 EA EA202092692A patent/EA202092692A1/en unknown
- 2019-06-17 JP JP2020569883A patent/JP7382353B2/en active Active
- 2019-06-17 MX MX2020013630A patent/MX2020013630A/en unknown
- 2019-06-17 US US16/443,298 patent/US10980784B2/en active Active
- 2019-06-17 CN CN201980047384.3A patent/CN112423843B/en active Active
- 2019-06-17 BR BR112020025283-2A patent/BR112020025283A2/en unknown
- 2019-06-17 AU AU2019286524A patent/AU2019286524A1/en active Pending
- 2019-06-17 SG SG11202012447YA patent/SG11202012447YA/en unknown
- 2019-06-17 EP EP23209520.8A patent/EP4302827A3/en active Pending
- 2019-06-17 KR KR1020217001301A patent/KR20210021534A/en unknown
- 2019-06-17 EP EP19819402.9A patent/EP3813946B1/en active Active
- 2019-06-17 CA CA3103282A patent/CA3103282A1/en active Pending
- 2019-06-17 CN CN202311390677.6A patent/CN117843659A/en active Pending
-
2020
- 2020-11-25 US US17/104,771 patent/US11944605B2/en active Active
- 2020-12-09 IL IL279329A patent/IL279329A/en unknown
- 2020-12-15 CO CONC2020/0015747A patent/CO2020015747A2/en unknown
-
2023
- 2023-11-06 JP JP2023189414A patent/JP2024012524A/en active Pending
- 2023-12-04 US US18/528,215 patent/US20240173305A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20240173305A1 (en) | 2024-05-30 |
US20210220339A1 (en) | 2021-07-22 |
JP7382353B2 (en) | 2023-11-16 |
AU2019286524A1 (en) | 2021-01-07 |
KR20210021534A (en) | 2021-02-26 |
EP3813946A1 (en) | 2021-05-05 |
CN117843659A (en) | 2024-04-09 |
CO2020015747A2 (en) | 2020-12-21 |
EP3813946A4 (en) | 2022-06-01 |
MX2020013630A (en) | 2021-04-28 |
EA202092692A1 (en) | 2021-04-21 |
US11944605B2 (en) | 2024-04-02 |
US10980784B2 (en) | 2021-04-20 |
IL279329A (en) | 2021-01-31 |
CN112423843A (en) | 2021-02-26 |
WO2019241789A1 (en) | 2019-12-19 |
CN112423843B (en) | 2023-11-28 |
CA3103282A1 (en) | 2019-12-19 |
US20190388401A1 (en) | 2019-12-26 |
JP2021528396A (en) | 2021-10-21 |
EP3813946B1 (en) | 2024-05-22 |
EP4302827A2 (en) | 2024-01-10 |
EP4302827A3 (en) | 2024-03-13 |
JP2024012524A (en) | 2024-01-30 |
BR112020025283A2 (en) | 2021-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL275468A (en) | Incretin analogs and uses thereof | |
IL275469A (en) | Incretin analogs and uses thereof | |
IL273236A (en) | Pyrazolopyrimidinone compounds and uses thereof | |
IL279329A (en) | Rapamycin analogs and uses thereof | |
FI3687999T3 (en) | Rapamycin derivatives | |
GB202005105D0 (en) | n | |
GB201803568D0 (en) | Novel compounds and uses | |
GB201818605D0 (en) | Nivel use | |
GB201820521D0 (en) | n | |
IL277502A (en) | Compounds and uses thereof | |
IL279483A (en) | Cyanotriazole compounds and uses thereof | |
GB201818712D0 (en) | Accelerometer | |
GB201918689D0 (en) | n | |
GB201701986D0 (en) | n | |
GB201701848D0 (en) | Reciever | |
ZA201904806B (en) | Glove structure | |
GB201813378D0 (en) | n | |
GB2570714B (en) | Accelerometers | |
GB201803571D0 (en) | Component | |
GB201801102D0 (en) | New compounds and uses | |
GB202002530D0 (en) | N | |
EP3897667A4 (en) | Salicyl-adenosinemonosulfamate analogs and uses thereof | |
GB201813568D0 (en) | Component | |
GB201806349D0 (en) | New compounds and uses | |
GB201707846D0 (en) | Use |